期刊
JOURNAL OF HUMAN HYPERTENSION
卷 26, 期 5, 页码 295-305出版社
SPRINGERNATURE
DOI: 10.1038/jhh.2011.31
关键词
grey matter volume; brain atrophy; magnetic resonance imaging
资金
- NIH [NHLBI HL57529]
- PJG [HL-R01-089850, MH-K01-070616]
- NR [R37, AG011230]
- ADNI (NIH) [U01 AG024904]
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering (NIBIB)
- Pfizer Inc.
- Wyeth Research
- Bristol-Myers Squibb
- Eli Lilly and Company
- GlaxoSmithKline
- Merck Co. Inc.
- AstraZeneca AB
- Novartis Pharmaceuticals Corporation
- Alzheimer's Association
- Eisai Global Clinical Development, Elan Corporation Plc
- Forest Laboratories
- Institute for the Study of Aging
- US Food and Drug Administration
The aim of the study was to determine whether the reduction in brain grey matter volume associated with hypertension persisted or was remediated among hypertensive patients newly treated over the course of a year. A total of 41 hypertensive patients were assessed over the course of a 1-year successful anti-hypertensive treatment. Brain areas identified previously in cross-sectional studies differing in volume between hypertensive and normotensive individuals were examined with a semi-automated measurement technique (automated labelling pathway). Volumes of grey matter regions were computed at baseline after a year of treatment and compared with archival data from normotensive individuals. Reductions in regional grey matter volume over the follow-up period were observed despite successful treatment of blood pressure (BP). The comparison group of older, but normotensive, individuals showed no significant changes over a year in the regions tested in the treated hypertensive group. These novel results suggest that essential hypertension is associated with regional grey matter shrinkage, and successful reduction of BP may not completely counter that trend. Journal of Human Hypertension (2012) 26, 295-305; doi:10.1038/jhh.2011.31; published online 14 April 2011
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据